Congenital syphilis: Difference between revisions
From IDWiki
(→: linkified) |
(→: added postpartum management) |
||
Line 29: | Line 29: | ||
* Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis |
* Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis |
||
* Treat affected infant with [[Is treated by::penicillin G]] 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days |
* Treat affected infant with [[Is treated by::penicillin G]] 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days |
||
* Can treat lower-risk infants with [[Is treated by::benzathine penicillin G]] 50,000 U/kg IM once |
|||
=== Canadian guidelines === |
|||
{| class="wikitable sortable" |
|||
! colspan=3 | Maternal treatment |
|||
! rowspan=2 | Neonatal assessment |
|||
! colspan=4 | Recommendations |
|||
|- |
|||
! Type |
|||
! Timing |
|||
! Outcome |
|||
! Monthly exam for 3 months |
|||
! Serology |
|||
! CBC/CSF/x-rays |
|||
! Treatment |
|||
|- |
|||
| any |
|||
| before pregnancy |
|||
| adequate, with no RPR rise and no risk factors for reinfection |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| none |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| >4 weeks before delivery |
|||
| adequate |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months |
|||
| |
|||
| none |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| ≤4 weeks before delivery |
|||
| |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| usually |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| |
|||
| not penicillin |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| usually |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| before or during pregnancy |
|||
| RPR not decline as expected |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| usually |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| before pregnancy |
|||
| inadequate, or reinfection |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| consider |
|||
| depends on risk and results of assessments |
|||
|- |
|||
| primary, secondary, or early latent |
|||
| during pregnancy |
|||
| unknown |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| consider |
|||
| depends on risk and results of assessments |
|||
|- |
|||
| primary or secondary syphilis |
|||
| during pregnancy |
|||
| inadequate |
|||
| |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| late latent |
|||
| during or after pregnancy |
|||
| adequate |
|||
| |
|||
| no |
|||
| 0, 6, and 18 months |
|||
| no |
|||
| none |
|||
|- |
|||
| any |
|||
| during pregnancy |
|||
| |
|||
| follow-up unlikely |
|||
| yes |
|||
| 0, 3, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| consider |
|||
| depends on risk and results of assessments |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| treponemes on tissue examination |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| infant's RPR four-fold or greater than the mother's at birth |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| four-fold rise in infant's titre |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| signs of congenital syphilis at any age |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| reactive RPR+TT at 12 months |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| reactive TT at 18 months |
|||
| yes |
|||
| 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months |
|||
| yes |
|||
| 10 days |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| RPR+TT reactive at 6 months |
|||
| — |
|||
| — |
|||
| yes |
|||
| usually |
|||
|} |
|||
===US guidelines=== |
|||
{| class="wikitable" |
|||
! colspan=2 | Initial neonatal assessment |
|||
! colspan=2 | Maternal treatment |
|||
! colspan=2 | Recommendations |
|||
|- |
|||
! RPR/VDRL |
|||
! Evaluation |
|||
! Timing |
|||
! Type |
|||
! Evaluation |
|||
! Treatment |
|||
|- |
|||
| rowspan=2 | any |
|||
| physical exam suggests congenital syphilis |
|||
| rowspan=2 | any |
|||
| rowspan=2 | any |
|||
| rowspan=2 | LP and CBC |
|||
| rowspan=2 | 10 days |
|||
|- |
|||
| spirochete in a clinical specimen |
|||
|- |
|||
| ≥ fourfold maternal titre |
|||
| any |
|||
| any |
|||
| any |
|||
| LP and CBC |
|||
| 10 days |
|||
|- |
|||
| rowspan=4 | less than fourfold maternal titre |
|||
| rowspan=4 | normal |
|||
| rowspan=2 | before pregnancy |
|||
| adequate |
|||
| none |
|||
| none (or one dose) |
|||
|- |
|||
| reinfection or relapse (≥4-fold increase in titre) |
|||
| LP and CBC |
|||
| one dose (unless exam at all abnormal) |
|||
|- |
|||
| rowspan=2 | during pregnancy |
|||
| adequate |
|||
| none |
|||
| one dose (or none) |
|||
|- |
|||
| inadequate or suboptimal |
|||
| LP and CBC |
|||
| one dose (unless exam at all abnormal) |
|||
|- |
|||
| rowspan=2 | nonreactive |
|||
| rowspan=2 | normal |
|||
| rowspan=2 | during pregnancy |
|||
| adequate |
|||
| none |
|||
| none (or one dose) |
|||
|- |
|||
| inadequate or suboptimal |
|||
| none |
|||
| one dose |
|||
|} |
|||
* LP should be sent for VDRL, cell count, protein |
|||
* CBC with differential for platelet count |
|||
[[Category:Sexually-transmitted infections]] |
[[Category:Sexually-transmitted infections]] |
Revision as of 21:58, 4 July 2020
Background
Epidemiology
- Rare, with about 20 per 100,000 live births in the US
- Greatest risk to child is with untreated primary maternal syphilis
Pathophysiology
- Transplacental transmission while bacteremic
- Can be transmitted during delivery, as well
Clinical Presentation
- Mothers typically have had no prenatal care
- To the fetus, can cause spontaneous abortion (40% in untreated primary syphilis), preterm delivery, polyhydramnios, intra-uterine growth restriction, hydrops fetalis, or intra-uterine fetal demise
- At birth, two thirds of affected neonates are asymptomatic, with disease developing over the following 6 weeks
- Early disease, within the first two years, includes:
- Rhinitis (called snuffles, often bloody and copious), desquamating rash, hepatosplenomegaly, lymphadenopathy, and skeletal abnormalities
- Also: condyloma lata, vesicular rash or bullous rash, periostitis, hydrops, thrombocytopenia, hepatitis, jaundice, or glomerulonephritis
- About 20% involve the CNS
- Late disease, after the first two years, includes:
- Sensorineural hearing loss, intellectual impairment, saddle nose deformity, frontal bossing, jaw, dental, and palatal abnormalities including Hutchison teeth, saber tibia, short stature, and keratitis
Diagnosis
- Darkfield microscopy and/or PCR on body fluids, including nasal discharge or CSF
- Serology
- RPR on infant blood (not cord blood), paired with maternal RPR
- May need CSF analysis
- Also check HIV serology, skeletal survey, chest x-ray, ophthalmology, audiology, and cranial ultrasound
Management
- Treat syphilis in pregnancy with high-dose penicillin to prevent congenital syphilis
- Treat affected infant with penicillin G 50,000 U/kg/day IV q12h for the first 7 days of life, followed by q8h to complete a total of 10 days
- Can treat lower-risk infants with benzathine penicillin G 50,000 U/kg IM once
Canadian guidelines
Maternal treatment | Neonatal assessment | Recommendations | |||||
---|---|---|---|---|---|---|---|
Type | Timing | Outcome | Monthly exam for 3 months | Serology | CBC/CSF/x-rays | Treatment | |
any | before pregnancy | adequate, with no RPR rise and no risk factors for reinfection | none | ||||
primary, secondary, or early latent | >4 weeks before delivery | adequate | yes | 0, 3, 6, and 18 months | none | ||
primary, secondary, or early latent | ≤4 weeks before delivery | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | ||
primary, secondary, or early latent | not penicillin | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | ||
primary, secondary, or early latent | before or during pregnancy | RPR not decline as expected | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | usually | |
primary, secondary, or early latent | before pregnancy | inadequate, or reinfection | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments | |
primary, secondary, or early latent | during pregnancy | unknown | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments | |
primary or secondary syphilis | during pregnancy | inadequate | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |
late latent | during or after pregnancy | adequate | no | 0, 6, and 18 months | no | none | |
any | during pregnancy | follow-up unlikely | yes | 0, 3, and 18 months; if not treated, also at 1, 2, and 12 months | consider | depends on risk and results of assessments | |
treponemes on tissue examination | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
infant's RPR four-fold or greater than the mother's at birth | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
four-fold rise in infant's titre | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
signs of congenital syphilis at any age | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
reactive RPR+TT at 12 months | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
reactive TT at 18 months | yes | 0, 3, 6, and 18 months; if not treated, also at 1, 2, and 12 months | yes | 10 days | |||
RPR+TT reactive at 6 months | — | — | yes | usually |
US guidelines
Initial neonatal assessment | Maternal treatment | Recommendations | |||
---|---|---|---|---|---|
RPR/VDRL | Evaluation | Timing | Type | Evaluation | Treatment |
any | physical exam suggests congenital syphilis | any | any | LP and CBC | 10 days |
spirochete in a clinical specimen | |||||
≥ fourfold maternal titre | any | any | any | LP and CBC | 10 days |
less than fourfold maternal titre | normal | before pregnancy | adequate | none | none (or one dose) |
reinfection or relapse (≥4-fold increase in titre) | LP and CBC | one dose (unless exam at all abnormal) | |||
during pregnancy | adequate | none | one dose (or none) | ||
inadequate or suboptimal | LP and CBC | one dose (unless exam at all abnormal) | |||
nonreactive | normal | during pregnancy | adequate | none | none (or one dose) |
inadequate or suboptimal | none | one dose |
- LP should be sent for VDRL, cell count, protein
- CBC with differential for platelet count